About Alvogen
Alvogen is a Healthcare company based in Montville (United States) founded in 2009, and was acquired by Lotus in September 2025. Pharmaceutical products are developed and marketed globally. Alvogen has raised $155.92 million across 2 funding rounds from investors including Morgan Stanley, Lotus and IMM Investment. Alvogen has completed 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals and Dolphin. Its chief executive, as recorded, is Lisa Graver. Alvogen offers products and services including Generic Drugs and Injectables. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Alvogen, Inc.
Company details
Alvogen was founded in 2009 and is headquartered in Montville, United States. Operations in the pharmaceutical sector involve developing, in-licensing, manufacturing, and marketing a range of products, including generic drugs, branded items, injectables, and complex medications such as inhalation therapies and 505(b)(2) formulations. A research and development program supports the pipeline, while ethical practices and transparency guide interactions with healthcare providers.
- Headquarters Montville, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website alvogen.com
- Social LinkedIn X Facebook
- Acquired by Aztiq (May 2022)
- Legal Name Alvogen, Inc
- Total Equity Funding$155.92M (USD)
in 2 rounds
- Latest Funding Round$100M (USD), Series D
Jun 2021
- InvestorsMorgan Stanley
& 4 more
- Investments & AcquisitionsCounty Line Pharma
& 6 more
- Acquired by
Products & Services of Alvogen
Alvogen offers a comprehensive portfolio of products and services, including Generic Drugs and Injectables.
Generic drugs are developed and marketed by Alvogen as part of its core portfolio to provide accessible alternatives to branded medications
Injectables are manufactured and distributed by Alvogen, focusing on complex, high-value products that support various medical treatments
Funding Insights of Alvogen
Alvogen has successfully raised a total of $155.92M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155.92M
- Total Rounds 2
- Last Round Series D β $100M
- First Round $55.92M
(Jun 2012)
- Investors Count 2
All 2 funding rounds of Alvogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $100M | Series D | β | Morgan Stanley | β |
| Jun 2012 | $55.92M | Series C | β | IMM Private Equity | β |
5 investors in total: 5 institutional.
Investors in Alvogen
Alvogen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Lotus and IMM Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
IMM Investment is recognized as a leading multi-asset alternative investment firm in Asia. | immpe.com | Seoul, South Korea | ||
Private equity investment firm focused on multiple sectors | pamplonafunds.com | London, United Kingdom | ||
Wealth management, investment advisory, and financial services are provided. | 1935 | morganstanley.com | New York, United States | |
Aztiq is focused on investments in pharmaceutical and biotechnology sectors. | 2009 | aztiq.com | Reykjavík, Iceland | |
Contract manufacturing for oral solid formulations is offered. | 1966 | lotuspharm.com | Taipei, Taiwan |
Investor details for Alvogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alvogen
89 people are tracked at Alvogen (29 in leadership, 5 in board & advisors, 55 in team).
| Name | Role | Group |
|---|---|---|
Lisa Graver | CEO | Leadership |
Robert Wessman | Chairman & CEO | Leadership |
Arni Hardarson | Deputy to the CEO | Leadership |
Young-Hoon Kwon | Marketing Director | Leadership |
Lana Puzanova | Senior Director, US Controller | Leadership |
joohwa ha | Head Of Commercial Excellence(전무) | Leadership |
Mohit Patwardhan | Director- Legal and IP Litigation - APAC | Leadership |
Anita Sevcenkova | IP Director B2B | Leadership |
Renaat Janssen | Executive Vice President APAC | Executive Chairman APAC | Leadership |
William Suchy | Director Of Accounting | Leadership |
Prashant Godse | Vice President- Business Development | Leadership |
Travis Roberts | VP Sales and Marketing | Leadership |
Dr. Deepali K. | Director, Portfolio & New Products Strategy | Leadership |
Chia-wei Kin | Director, Chairman office / Special Assistant to APAC CEO | Leadership |
Eunsun Choi | Vice President | Leadership |
Gwen Hsieh | VP of IT, Alvogen APAC | Leadership |
John Garbarini | Director of Revenue Accounting | Leadership |
Evan Lee | Director, Legal Affairs | Leadership |
Mary Hutchason | Executive Assistant To The Ceo/office Manager | Leadership |
Michael Olivi | Senior Director of Sales Alvogen | Leadership |
69 more people are available in the full profile.
Complete people profiles for Alvogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alvogen
Alvogen has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include County Line Pharma, County Line Pharmaceuticals and Dolphin.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Online drug information is provided via GRALISE's digital platform. | gralise.com | Lake Forest, United States | 2010 | Jan 2020 | $75M | |
Saline nasal rinse solutions are manufactured for adults and children. | dolphin.ru | Russia | 0 | Dec 2016 | β’β’β’β’ | |
Generic solid and liquid dosage forms are manufactured and marketed. | countylinepharma.com | Milwaukee, United States | 2007 | Mar 2016 | $300M | |
Generic pharmaceutical products are manufactured across therapeutic categories. | countylinepharmaceuticals.com | Brookfield, United States | 2007 | Mar 2016 | β’β’β’β’ | |
Antiviral syrup for children against influenza and infections is manufactured. | orvirem.ru | Russia | 0 | Jun 2015 | β’β’β’β’ | |
Contract manufacturing for oral solid formulations is offered. | lotuspharm.com | Taipei, Taiwan | 1966 | Jan 2014 | β’β’β’β’ | |
Manufacturer of pharmaceuticals and food supplements | labormed.eu | Bucharest, Romania | 1991 | Dec 2012 | β’β’β’β’ |
Complete acquisition details for Alvogen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alvogen
13 dated milestones of Alvogen across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Alvogen is founded.
- Funding First funding round of $55.9M.
- Acquisition Acquires Labormed.
- Acquisition Acquires Lotus.
- Exit Acquired by Pamplona Capital Management.
- Acquisition Acquires Orvirem.
- Acquisition Acquires County Line Pharmaceuticals.
- Acquisition Acquires County Line Pharma.
- Acquisition Acquires Dolphin.
- Acquisition Acquires GRALISE.
- Funding Latest funding round, Series D, of $100.0M.
- Exit Acquired by Aztiq.
- Exit Acquired by Lotus.
Web traffic of Alvogen
The website of Alvogen (alvogen.com) receives about 9.2K visits a month and ranks #2,534,262 among all websites worldwide, #3,479 in Biotechnology and Pharmaceuticals.
- Monthly visits9.2K
▼ 6% vs previous month
- Unique visitors5.1K
per month
- Global rank#2,534,262
among all websites
- Category rank#3,479
Health · Biotechnology and Pharmaceuticals
- Bounce rate63%
- Pages per visit1.3
- Average visit14 sec
- DevicesDesktop 25% Β· Mobile 75%
Websites whose visitors overlap most with Alvogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmaceutical-business-review.com | 100% | #2,626,966 | View details | ||
| takeda.com | 99% | 620.1K | #93,966 | View details | |
| parpharm.com | 95% | View details | |||
| lannett.com | 91% | 18.2K | #1,443,152 | View details | |
| mylan.com | 78% | 26.4K | #1,585,141 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 17 similar websites and full traffic analytics for Alvogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Alvogen (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alvogen
Complete news archive for Alvogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alvogen
Alvogen was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Alvogen is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.
Lisa Graver is the CEO of Alvogen, as recorded in our data.
Alvogen is a funded company, having raised a total of $155.92M across 2 funding rounds to date. The company's 1st funding round was a Series C of $55.92M, raised on Jun 2012.
Alvogen was founded in 2009 and is headquartered in Montville, United States. Operations in the pharmaceutical sector involve developing, in-licensing, manufacturing, and marketing a range of products, including generic drugs, branded items, injectables, and complex medications such as inhalation therapies and 505(b)(2) formulations. A research and development program supports the pipeline, while ethical practices and transparency guide interactions with healthcare providers.
Alvogen offers Generic Drugs and Injectables.
Alvogen has made 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals, and Dolphin.
Alvogen has 5 investors. Key investors include Morgan Stanley, Lotus, IMM Investment, Aztiq, and Pamplona Capital Management.
Alvogen operates through Alvogen, Inc.
Yes. Alvogen was acquired by Aztiq in May 2022.

